Diffuse Large B Cell Lymphoma: Five Factors For A Prognosis

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-established and reliably predictive model known as the Revised International Non-Hodgkin's Lymphoma Prognostic Index (IPI or R-IPI). In order for this to be applicable, the patient must have been diagnosed with DLBCL and be treated with Rituximab-based combination chemotherapy, namely R-CHOP.

The Index uses five factors for a prognosis, assigns a single point to each factor if true, then takes the sum total and uses it to determine a survival rate percentage.

Prognosis Factors

  • AGE: Patients over the age of 60 add one point.
  • SERUM LDH: If LDH (lactate dehydrogenase) levels are elevated, add one point.
  • PERFORMANCE STATUS: If the patient's performance status is determined to be between 2 and 4 add one point.
  • DISEASE STAGE: If the patient is diagnosed at stage III or stage IV, add one point.
  • EXTRANODAL INVOLVEMENT: If the patient's lymphoma involves more than one extranodal site (such as bone, liver, spleen, or bone marrow), add one point.

So a patient can have between 0 and 5 points. Here's what those totals mean for a prognosis:

0 points

  • Prognosis: Very good
  • Predicted 4-year progression-free survival: 94 percent
  • Overall survival: 94 percent

1-2 points

  • Prognosis: Good.
  • Predicted 4-year progression-free survival: 80 percent
  • Overall survival: 79 percent

3-5 points

  • Prognosis: Poor
  • Predicted 4-year progression-free survival:53 percent
  • Overall survival: 55 percent

Conclusion

This index has shown to be a reasonably predictive model in determining a prognosis; however, it will not hold true for every single diagnosed and treated patient.

Related Reading

Photo: Pexels

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...